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1 INTRODUCTION 
Bacterial biofilms are well-organized bacterial cell aggregates on various surfaces, which 
constitute a successful protection mechanism for planktonic bacterial cells to survive and 
proliferate in hostile environments (Donlan 2002; Simões et al. 2010). To date, 
biofilm-associated infections in medical devices represent a major cause of morbidity and 
mortality among patients (Shirtliff and leid 2009; Simões et al. 2010; Chen et al. 2013a). 
As a result, various biofilm control approaches, generally focus on changing the surface 
characteristics, have been applied to practice (Champ et al. 1987), but often toxic 
substances are used (Evans et al. 1995; Chen et al. 2013a). The use of biocompatible 
bacteria-repellent agents such as hydrophobins, fluoropolymers and polydimethylsiloxanes 
(Rieder et al. 2011; Brady 2000; Krishnan et al. 2008) to prevent bacterial colonization on 
surfaces, thus negating the use of toxic substances is a new biofilm control strategy over 
the last fifteen years.  
 
Hydrophobins are a family of small adhesive proteins exclusively produced by filamentous 
fungi and play a crucial role in fungal growth and development (Wösten and Scholtmeijer 
2015; Wessels 1997). Apart from rich in hydrophobic amino acids, all of these fungal 
proteins possess eight cysteine residues at conserved positions that form four 
intramolecular disulfide bridges (Linder et al. 2005). Hydrophobins are extremely 
surface-active proteins; they are able to self-assemble into stable monolayers at 
hydrophilic-hydrophobic interfaces (Wösten 2001), and thereby altering the surface 
wettability of solids, from hydrophilic to hydrophobic and vice versa (Wösten and de 
Vocht 2000; Lugones et al. 1996). Due to these unique properties, many potential 
applications have been proposed for hydrophobins, including uses as emulsifiers in food 
products (Cox et al. 2008) and anti-biofilm agents (Rieder et al. 2011). 
 
However, in practice, native hydrophobin coatings generally have no impact on bacterial 
surface colonization, because of the lack of being antibacterial by these fungal proteins 
themselves (Rieder et al. 2011). This finding has led to numerous proposals in developing 
fusion hydrophobins that tethered with antibiotics, specific enzymes or antimicrobial 
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peptides to avoid or retard bacterial colonization on surfaces (Rieder et al. 2011). As a 
potential candidate, antimicrobial peptides possess preferable characteristics in comparison 
with antibiotics, including broad-spectrum antimicrobial activity, rapid onset of cell killing 
(Hancock and Sahl 2006), and low propensity to cause drug resistance among pathogens 
(Steckbeck et al. 2014). 
 
The aim of this study was to explore the feasibility of using recombinant fusion 
hydrophobins to control bacterial growth. In the first part of the thesis, bacterial biofilms 
and the corresponding control strategies, hydrophobins and the potential applications, 
antimicrobial peptides, especially antimicrobial peptides (Bac8c and P11-5) used in this 
study, and the Pichia pastoris protein expression system are reviewed. In the second part of 
the thesis, methods for molecular cloning, heterologous gene expression, protein 
identification, purification and characterization are described. In the final sections, the 
antibacterial potential of these recombinant fusion hydrophobins are evaluated and 
discussed.   
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2 LITERATURE REVIEW 
2.1 Bacterial biofilms  
Bacterial biofilms are well-organized bacterial cell aggregates on various surfaces, such as 
metals, plastics, biological tissues, implant materials and dental surfaces (Donlan 2002), 
which constitute a successful protection mechanism for planktonic bacterial cells to 
survive and proliferate in hostile environments (Simões et al. 2010). There is no denying 
that some bacterial biofilms (e.g. gut flora) are essential to human health, physiology and 
development, like Eubacterium spp., Bifidobacterium spp. and Ruminococcus spp. 
(Neufeld et al. 2009). However, under most circumstances, biofilms by human bacterial 
pathogens on indwelling medical devices, artificial implants and daily care products that 
are directly in contact with the human body, such as bile stents, urinary catheters, artificial 
skeletons and joints, and contact lens pose a critical medical problem (Simões et al. 2010; 
Costerton et al. 2005), which in turn may lead to acute infections and chronic illnesses 
(Bryers 2008; Bjarnsholt 2013). Many pathogenic bacteria can form biofilms on surfaces, 
including both gram-positive (e.g. Listeria monocytogenes, Staphylococcus aureus and 
Enterococcus faecalis) and gram-negative (Escherichia coli, Pseudomonas aeruginosa and 
Klebsiella pneumoniae) bacteria (Chen et al. 2013a). 
 
One well-accepted process of bacterial biofilm development is characterized by 5 stages 
(Hall-Stoodley et al. 2004) (Figure 1). (1) Reversible attachment of bacteria to surfaces. In 
this stage, planktonic bacterial cells use a variety of extracellular organelles and sticky 
membrane proteins for attaching to surfaces, including flagella (Daniels et al. 2004), pili 
(Sauer and Camper 2001) and stalks (Renner and Weibel 2011). (2) Irreversible attachment 
of bacteria to surfaces. Here bacteria are embedded within a ‘sticky scaffold’, a matrix of 
extracellular polymeric substances (EPS) that mainly contain nucleic acids, peptidoglycan, 
lipids/phospholipids and lipopolysaccharides (Sutherland 2001), and irreversibly cling to 
surfaces (Flemming and Wingender 2010). (3) Early development of biofilm architectures. 
Once bacterial cells are settled down on surfaces, they start to proliferate, accumulate and 
recruit free-floating bacterial cells from the surrounding environment (Stoodley et al. 2002), 
resulting in the formation of bacterial microcolonies with a diameter of tens or hundreds of 
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microns (Renner and Weibel 2011). Meanwhile, the EPS matrix acts as a ‘shield’ to protect 
the encapsulated bacterial cells from adverse factors in the surrounding environment, such 
as antibiotics, oxidizing agents, ultraviolet radiation (Flemming and Wingender 2010; 
Simões et al. 2005). (4) Maturation of biofilm architectures. Bacterial cells are further 
‘glued’ together by EPS, leading to the formation of complex three-dimensional biofilm 
structures. For example, water channels that help to distribute nutrients and disposal of 
waste products within or outside of the biofilm matrix (Stoodley et al. 1994). (5) 
Detachment and dispersion of bacteria from mature biofilms. Bacterial cells detach from 
mature biofilms and subsequently disperse into the surrounding environment, where they 
may act as ‘germs’ for a new round of biofilm development (Costerton et al. 1987; Fey et 
al. 2010). 
 
 
Figure 1. Schematic diagram of bacterial biofilm development on a surface. (1) Reversible attachment of 
bacteria to surfaces. (2) Irreversible attachment of bacteria to surfaces. (3) Early development of biofilm 
architectures (microcolonies). (4) Maturation of biofilm architectures. (5) Detachment and dispersion of 
bacteria from mature biofilms (Figure adapted from Stoodley et al. 2002).  
 
Bacterial biofilm inhibitors as potential drugs 
Bacterial cells growing in biofilms are highly resistant to antibacterial agents (Smith 2005; 
Olson et al. 2002). This resistance is supposed to be due to a lower reproduction rate of 
bacterial cells within biofilms and the barrier effect of EPS shell (Davies 2003; Lewis 2010; 
Stewart and Costerton 2001). For example, Ito et al. (2009) found that bacteria Escherichia 
coli showed an increased ampicillin resistance when it was grown as biofilms on an abiotic 
surface. Usually these biofilm-associated bacterial cells can be between 100-1000 times 
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more resistant to antibiotics when compared with their planktonic counterparts (Gristina 
1987), which makes them difficult to be eradicated with conventional antibiotic therapies 
(Chen et al. 2013a). In addition, overuses of antibiotics in bacterial biofilm therapies may 
give a rise to the antibiotic resistance among bacterial pathogens (Weinstein 2001). 
Antibiotic resistances in Escherichia coli, Staphylococcus aureus and Klebsiella 
pneumoniae such as multiple beta-lactam antibiotic resistance is one of the most urgent 
public health problems nowadays (Muir and Weinbren 2010; Yong et al. 2009; Grundmann 
et al. 2006). 
  
The initial stage of bacterial biofilm development is a surface-dependent reversible step; 
surface characteristics like wettability (Privett et al. 2011), roughness (Truong et al. 2010) 
and protein adsorption capacity (Stallard et al. 2012) may play an important role in 
facilitating bacterial colonization on surfaces. Based on these postulations, a research 
group at Harvard University developed a novel bacteria-repellent surface coating agent 
called SLIPS (Slippery-Liquid-Infused Porous Surfaces) (Wong et al. 2011). In the 
practical study, significant inhibition of Pseudomonas aeruginosa, Escherichia coli and 
Staphylococcus aureus biofilm development was observed on a SLIPS-coated surface, 
under both static and realistic flow cultivation conditions (Wyss Institute, Harvard 
University). Weickert et al. (2011) coated plastic bile stents with the recombinant fusion 
hydrophobin H*Protein A (from BASF SE), decreased microbial adhesion and serum 
protein adsorption were observed on these hydrophobin-treated bile stents.   
 
Other attempts have been focused on giving surfaces with an acquired antibacterial activity. 
This attempt is achieved primarily by incorporating antibacterial agents into/onto surface 
materials, such as antibiotics (Hickok and Shapiro 2012; Raad et al. 1997; Liu et al. 2012), 
chemicals (Jaramillo et al. 2012) and antimicrobial peptides (Costa et al. 2011; Tan et al. 
2014). 
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2.2 Hydrophobins 
Hydrophobins are a family of small (about 100 amino acids), amphipathic proteins, which 
are exclusively produced by filamentous fungi (Bayry et al. 2012; Wösten and 
Scholtmeijer 2015; Linder et al. 2005) and play a crucial role in fungal growth and 
development (Wösten and Willey 2000; Wessels 1997). These fungal proteins have been 
regarded as one of the most surface-active proteins known (Linder et al. 2005); they are 
able to self-assemble into amphipathic monolayers at hydrophobic-hydrophilic interfaces, 
for example, between air and water (Wösten et al. 1993), water and oil (Wang et al. 2004), 
hydrophobic surfaces and water, and hydrophilic surfaces and air (Wösten et al. 1994), and 
thereby altering the surface wettability of solids, from hydrophilic to hydrophobic 
(Lugones et al. 1996) and vice versa (Wösten et al. 1993) (Figure 2). 
 
 
Figure 2. Self-assembly of hydrophobins on surfaces. (A) Hydrophobin coating makes the hydrophobic 
surface hydrophilic (water contact angle [WCA], ranging between 22 and 63°). (B) Hydrophobin coating 
makes the hydrophilic surface hydrophobic (WCA, 110°). (1) If the WCA is smaller than 90°, the surface is 
considered as hydrophilic. (2) If WCA is greater than 90°, the surface is considered as hydrophobic. (3) ○ 
hydrophilic region ● hydrophobic region (Figure adapted from Wösten and de Vocht 2000). 
 
Hydrophobins show very low amino acid sequence homology in general, but all of them 
contain eight cysteine residues at conserved positions that form four intramolecular 
disulfide bridges with the conserved pattern (cys1-cys6, cys2-cys5, cys3-cys4, and 
cys7-cys8) (Kwan et al. 2006; Linder et al. 2005) (Figure 3). There are two categories of 
hydrophobins, class I and class II, which are firstly classified by Wessels (1994) based on 
biophysical properties, hydropathy patterns (Kyte and Doolittle 1982), and film-forming 
patterns of hydrophobins (Wessels 1997). Class I hydrophobins, such as SC3 of 
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Schizophyllum commune, EAS of Neurospora crassa and HGFI of Grifola frondosa can 
form rigid and highly insoluble aggregates on hydrophilic surfaces (e.g. mica and 
polystyrene plates) (Lugones et al. 1996), and can only be dissociated by strong acids (e.g. 
100% formic acid or trifluoroacetic acid). In contrast, class II hydrophobins, including 
HFBI and HFBII of Trichoderma reesei can form less stable monolayers on hydrophilic 
surfaces, and can easily be dissociated by 60% ethanol or 2 % SDS (Linder et al. 2005; 
Wösten et al. 1993). 
 
 
Figure 3. Ribbon diagram of the class I hydrophobin EAS of Neurospora crassa (Figure adapted from Bayry 
et al. 2012).    
 
Application prospects of hydrophobins 
Due to their amphipathic nature and self-assembly characteristics, many potential 
applications of hydrophobins have been proposed (Linder et al. 2005; Linder 2009; Wösten 
and Scholtmeijer 2015; Khalesi et al. 2012). Here applications in biotechnology and food 
industry are briefly summarized, including uses in protein/peptide immobilization or 
purification, food production and quality control, and anti-biofilm therapy. 
 
Immobilization of proteins and peptides as hydrophobin fusions 
The stable nanostructure of hydrophobin assembles on surfaces makes them suitable for 
immobilization of proteins/peptides (Linder et al. 2005). Niu et al. (2012a) have studied the 
surface modification characteristics of the class I hydrophobin HGFI of Grifola frondosa, 
and its fusion with a short human blood outgrowth endothelial cells (HBOECs) binding 
ligand, TPS (NH2-TPSLEQRTVYAK). The TPS-linker-HGFI fusion could be efficiently 
and rigidly immobilized onto a hydrophobic surface, as analyzed by water contact angle 
(WCA) and X-ray photoelectron spectroscopy (XPS) measurements. More importantly, the 
HBOECs binding activity of TPS was highly retained upon the immobilization. Linder et 
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al. (2002) used two class II hydrophobins HFBI and HFBII of Trichoderma reesei to 
immobilize the cellulose endoglucanase I catalytic core (EGI-core) of T. reesei, onto both 
silanized glass and Teflon™ surfaces. The enzyme activity was remained unchanged after 
the immobilization.  
 
Purification of proteins as hydrophobin fusions in aqueous two-phase systems  
Aqueous two-phase system (ATPS), also called aqueous biphasic system (ABS) is 
frequently employed as a nondestructive method for purification of labile proteins (e.g. 
membrane proteins and enzymes) at large scales. The amphipathic nature of hydrophobins 
makes them suitable as a fusion partner for ATPS purification of proteins (Wösten et al. 
1993).  
 
Collén et al. (2002) used the class II hydrophobin HFBI of Trichoderma reesei for ATPS 
purification of the cellulose endoglucanase I (EGI) of T. reesei, with both non-ionic 
detergent and polymers. The ATPS purified EGI showed an unaffected catalytic activity 
with a good recovery rate of 90% at pilot scale, which appeared to be more efficient than 
EGI purified by other methods (Linder et al. 2005).   
 
Food production and quality control   
Gushing is an unpleasant quality index of carbonated beverages (e.g. beer, champagne and 
sparkling wine), a phenomenon where a carbonated beverage, without agitation, vigorously 
effervesces and jets out when the cap is removed (Linder et al. 2005; Sarlin et al. 2012). 
Haikara et al. (2006) concluded that hydrophobins (class II hydrophobins) of barley/malt 
microbiological contaminants, including pathogenic Fusarium poae and Nigrospora spp., 
and non-pathogenic Trichoderma reesei (HFBI and HFBII) are closely related with these 
gushing problems (Figure 4). This finding has led to the development of an immunological 
detection method for the evaluation of gushing potential of barley and malt materials 
(Haikara et al. 2006). 
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Figure 4. Class II hydrophobin HFBII of Trichoderma reesei causes gushing of beer. In this laboratory 
experiment, 50 μg purified hydrophobin HFBII was added to a 33 cl bottle of beer three days prior to opening 
(Figure adapted from Linder et al. 2005).    
 
On the other hand, due to their superior foaming abilities and foam stability. Hydrophobins 
can thus be used in many aerated foods where foams are important, including chocolate, 
ice cream and buttercream (Cox et al. 2009). Recently, a research group from Unilever UK 
has successfully used hydrophobins from edible mushrooms to mimic the texture and 
mouthfeel of fats. As a result, up to 50% of the fat could be removed from the food 
products without affecting the mouthfeel (Green et al. 2013; Cox et al. 2008).  
 
Biofilm control 
Adsorption of serum proteins plays an important role for bacterial colonization on surfaces 
(Donlan 2002; Palmer et al. 2007), including dental plaque formation and the primary 
stage of urinary tract infections (Bernsmann et al. 2008; Wösten and Scholtmeijer 2015). 
Stallard et al. (2012) and Geoghegan et al. (2013) concluded that the fibrinogen loading of 
a surface was closely related to its colonization potential of bacteria. Based on this fact, 
von Vacano et al. (2011) successfully used the recombinant fusion hydrophobin protein 
H*Protein B (from BASF SE), to prevent the non-specific absorption of serum proteins, 
such as BSA, casein and collagen on a 1-octanethiol-coated gold surface. Sarparanta et al. 
(2012) employed the class II hydrophobin HFBII of Trichoderma reesei to wrap thermally 
hydro-carbonized porous silicon (THCPSi) nano-particles. Significant reduction in the 
non-specific adsorption of plasma proteins, such as serum albumin and fibrinogen was 
observed in these hydrophobin-treated nano-particles.  
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2.3 Antimicrobial peptides  
Antimicrobial peptides (AMPs) are endogenous oligopeptide ‘antibiotics’, which are 
widely distributed in all classes of life (Lehrer and Ganz 1999; Brodgen et al. 2003) and 
generally execute a non-receptor mediated cell killing mechanism (Prenner et al. 1999) 
against the competing microorganisms (Boman 1995). Usually these small molecules are 
composed of less than 60 amino acid residues, with a net positive charge of +2 to +9 
provided by lysine, arginine or, in acidic environments, histidine, and a dominant 
proportion (>50%) of hydrophobic resides (Hancock and Sahl 2006; Brodgen 2005; Peters 
et al. 2010).  
 
 
Figure 5. Four major structural groups of antimicrobial peptides: (A) α-helical structure of magainin-2; (B) 
β-sheeted structure of β-defensin 1; (C) extended structure of indolicidin; (D) looped structure of gramicidin 
(Figure adapted from Peters et al. 2010). 
 
The classification of AMP is difficult owing to the limited amino acid sequence homology 
between these peptides, thus the further classification of AMPs is made on the basis of 
their secondary structures (Epand and Vogel 1999; Hancock and Sahl 2006). Folded AMPs 
are classified into four major structural groups (Figure 5): α-helical peptides (for example, 
cecropins, magainins, pexiganans and the human cathelicidin LL-37); β-sheeted peptides 
predominantly stabilized by more than one disulfide bridge (for example, human α- and 
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β-defensins and protegrins); extended peptides enriched with specific amino acids like 
proline, tryptophan, arginine and histidine (for example, indolicidin, bactenecin-5 and 
bactenecin-7); looped peptides coiled by one disulfide bridge (for example, gramicidin) 
(Peters et al. 2010; Hancock and Sahl 2006). 
 
Currently, more than 2,000 natural AMPs have been isolated from a wide range of 
organisms (more information can be found at http://aps.unmc.edu/AP/main.php). Some of 
them have been approved for clinical or food applications, including the cationic AMP 
(cAMP) gramicidin S for treatment of genital ulcers and the lantibiotic nisin for 
preservation of food products (Hancock and Sahl 2006). Of interest, AMPs exhibit a wide 
range of activities against various organisms, including gram-negative and gram-positive 
bacteria, fungi, enveloped viruses, parasites, and tumor cells with low propensity to cause 
drug resistance among pathogens (Baker et al. 1993; Hancock and Scott 2000; Hancock 
and Sahl 2006; Zasloff 2002; Chen et al. 2001; Hoskin and Ramamoorthy 2008). Due to 
these unique properties, AMPs are considered as attractive substitutes for conventional 
antibiotics to overcome the current drug resistance crisis (Hancock and Sahl. 2006; Lohner 
2001). 
 
Mechanisms of antimicrobial-peptide-mediated bacterial cell killing 
Despite their vast structural varieties, most AMPs kill bacterial cells by disrupting the 
cytoplasmic membrane integrity, resulting in the effusion of intracellular ions and organic 
solutes (Prenner et al. 1999), which in turn may lead to cell death. Although the exact 
mechanism by which AMPs disengage the bacterial cytoplasmic membrane is still not fully 
understood. Indisputably, AMPs must be initially attracted to the bacterial surface, and this 
step is thought to be facilitated by electrostatic interactions between AMPs and 
lipopolysaccharides (LPS) on the surface of Gram-negative bacteria, and wall-associated 
teichoic acids on the surface of Gram-positive bacteria (Figure 6) (Hancock 2001; Brogden 
2005).  
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Figure 6. Cartoon of the electrostatic attraction of the positively charged AMPs to the negatively charged 
bacterial envelopes (Figure adapted from Matsuzaki 2009). 
 
Once non-covalently attached to the bacterial surface, AMPs must traverse the compact 
bacterial outer wall before they can interact with the cytoplasmic membrane, by a process 
described by Hancock and coworkers as ‘self-promoted uptake’ (Hancock and Sahl 2006; 
Hancock 1997). This process is very important but rarely mentioned in many earlier 
studies. Take gram-negative bacteria as an example, the bacterial outer wall stability is 
maintained by native divalent cations (e.g. Mg
2+
 and Ca
2+
) via salt bridges (Ledebo 1976). 
AMPs show higher affinity to LPS than these native divalent cations and thus 
competitively displacing them, resulting a disruption of the bacterial outer wall integrity. 
This local disturbance in the bacterial out wall enables AMPs to pass through the bacterial 
outer wall and reach the negatively charged cytoplasmic membrane.  
 
Once reached the cytoplasmic membrane, AMPs start to interact with the anionic 
phospholipid head groups of the cytoplasmic membrane (Figure 6). At low peptide/lipid 
(P/L) molar ratios, AMPs are bound parallel onto the cytoplasmic membrane through 
hydrophobic and electrostatic interactions, and slightly stretch the cytoplasmic membrane 
(Yang et al. 2001; Brogden 2005). Once the P/L ratio surpasses a critical threshold, AMPs 
start to aggregate into bundles and subsequently insert into the cytoplasmic membrane 
interior, leading to the formation of transmembrane pores or detergent-like micelles 
(Brogden 2005; Melo et al. 2009), which in turn may lead to cell death. Three modes of 
action have been proposed based on the model membrane study with AMPs, they are: (1) 
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barrel-stave model (Ehrenstein and Lecar 1977); (2) carpet model (Pouny et al. 1992; 
Jenssen et al. 2006) and (3) toroidal pore model (Yamaguchi et al. 2002) (Figure 7).  
 
 
Figure 7. Modes of action of antimicrobial peptides: (A) barrel-stave model; (B) toroidal pore model; (C) 
carpet model (Figure modified from Brogden 2005). 
 
Alternative mechanisms of antimicrobial-peptide-mediated bacterial cell killing 
Most of the existing AMPs (>90%) act directly on the bacterial cytoplasmic membrane, via 
a non-receptor dependent membrane permeabilization process, as described in detail above. 
However, some early studies revealed that there is a distinct group of AMPs, which can kill 
bacteria in a non-lytic process (Bahar and Ren 2013). One example is AMP Buforin II, 
which kills bacteria by inhibiting DNA and RNA synthesis (Park et al. 1998). Increasing 
evidence indicates that there are several intracellular sites of AMP activity, including DNA 
and RNA (Park et al. 1998), intracellular enzymes, and ribosomes (Boman et al. 1993) 
(Figure 8).  
 
Figure 8. Schematic diagram of intracellular sites of antimicrobial peptide activity in Escherichia coli 
(Figure adapted from Brogden 2005). 
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Antimicrobial peptides P11-5 and Bac8c 
AMP P11-5 (NH2-GKLFKKILKIL) is a novel 11-amino-acid peptide derived from AMP 
BP76 (NH2-KKLFKKILKFL) with two amino acid substitutions (Qi et al. 2010). This 
peptide showed a board-spectrum antimicrobial activity against a wide range of pathogenic 
microorganisms, including gram-negative bacteria (E. coli and P. aeruginosa), 
gram-positive bacteria (S. aureus) and fungi (C. albicans and F. solani) without significant 
cytotoxicity to mammalian cells (Table 1).  
 
AMP Bac8c (NH2-RRWIVWIR) is a truncated 8-amino-acid peptide derived from AMP 
Bac2A (NH2-RAVRIVVIRALR), a C3A/C11A variant of bactenecin (also known as 
bovine dodecapeptide), with four amino acid substitutions (Hilpert et al. 2005). This 
peptide (Bac8c) is the smallest known antimicrobial peptide with broad-spectrum activity 
against a range of microorganisms, such as gram-positive bacteria (S. aureus and        
S. epidermidis), gram-negative bacteria (E. coli and P. aeruginosa) and a fungus        
(C. albicans) (Table 1).  
 
Table 1. Peptide properties: MICs (μg/ml) for five test pathogenic microorganisms  
a 
values were obtained from Qi et al. 2010.  
b
 values were obtained from Hilpert et al. 2005. 
 
P11-5 is a cationic (+4) AMP with a substantial proportion (7/11) of hydrophobic amino 
acid residues. The structural study of P11-5 showed that this peptide is mainly folded up 
into an amphipathic α-helix structure, with the positively charged hydrophilic residues 
localized on one side of the helix and the hydrophobic residues on the other side (Figure 
9). 
 
Peptide 
Name 
Peptide sequence 
(NH2-) 
Minimum inhibitory concentration (MIC, μg/ml) 
E. coli P. aeruginosa S. aureus C. albicans F. solani 
BP76
a
 
P11-5
a
 
Bac2A
b
 
Bac8c
b
 
KKLFKKILKFL 
GKLFKKILKIL 
RAVRIVVIRAR 
RRWIVWIR 
8 
3.1 
17 
2 
16 
12.5 
50 
8 
62.3 
12.5 
17 
2 
25 
3.1 
9 
8 
50 
12.5 
- 
- 
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Figure 9. Edmunson wheel projection of antimicrobial peptide P11-5. Black amino acids stand for 
hydrophilic amino acid, and white amino acids stand for hydrophobic amino acids (Figure modified from Qi 
et al. 2010).  
 
Due to its amphipathic and cationic nature, P11-5 may spontaneously interact with the 
negatively charged bacterial outer wall and rapidly disintegrate the cytoplasmic membrane 
by the ‘carpet-like’ mode of action (Ferre et al. 2006; Melo et al. 2009). The field emission 
scanning electron microscopy (FESEM) images of E. coli cells challenged by P11-5 
showed conspicuous membrane fraying and surface blistering, together with the effusion of 
intracellular materials (Figure 10).  
 
 
Figure 10. Field emission scanning electron microscopy (FESEM) images of Escherichia coli ATCC 8739 
cells untreated and treated with the antimicrobial peptide P11-5 for 15 min. (A) Untreated control; (B) 3.1 
μg/ml (MIC) (Figure adapted from Qi et al. 2010). MIC: minimum inhibition concentration. 
 
Bac8c is a cationic (+3) AMP with an abnormal low amount (< 50%) of hydrophobic 
amino acid residues. The secondary structure of Bac8c is typically α-helix, with its specific 
structure being anion-, pH- and detergent-dependent. For example, it adopts α-helical 
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structure in a zwitterionic solution and β-turn structure in anionic solutions (Wieczorek et 
al. 2010).  
 
Like the parent peptide Bac2A, Bac8c executes a two-stage mode of antimicrobial action, 
in a way not solely dependent on membrane depolarization as the cause of cell death 
(Spindler et al. 2011). In short, when Bac8c is present at concentrations that below the 
minimum inhibitory concentration (MIC), the bacterial cytoplasmic membrane integrity is 
well maintained (Figure 11B), while the cellular metabolism (e.g. ATP synthesis, 
NAD
+
/NADH balance and protein synthesis) is severely impaired. Upon the accumulation 
of a threshold concentration of Bac8c on microbial cytoplasmic membranes, the bacterial 
cytoplasmic membrane is rapidly (less than 5 min) depolarized via an unknown mechanism, 
resulting in the formation of transmembrane pores (between 2.2 and 3.3 nm) and effusion 
of intracellular ions and organic solutes (Figure 11C & D) (Lee and Lee 2015). 
 
 
Figure 11. Transmission electron microscopy (TEM) images of Escherichia coli ATCC 9637 cells untreated 
and treated with the antimicrobial peptide Bac8c for 30 min. (A) Untreated control. (B) 3 μg/ml (IC50). (C) 6 
μg/ml (MBC). (D) 30 μg/ml (5x the MBC) (Figure adapted from Spindler et al. 2011). MBC: minimum 
bactericidal concentration. IC50: the half maximal inhibitory concentration. 
 
2.4 The Pichia pastoris protein expression system   
Over the past few decades, scientists have learned how to identify, amplify and place genes 
into a variety of organisms that are different from the source organism (Macauley-Patrick 
et al. 2005). Meanwhile, in this proteomics era, the demand of proteins for scientific and 
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pharmaceutical research is steadily on the increase. Therefore, a major application of these 
transgenic organisms is to produce heterologous proteins (Macauley-Patrick et al. 2005; 
Adrio and Demain 2010). 
 
To date, bacterial protein expression systems are still predominately used in most 
laboratories for heterologous protein production, due to their simplicity of genetic 
manipulation, low cultivation costs and generally high yields, when compared with other 
protein expression platforms (Chen 2012). However, insufficient and incorrect 
post-translational modifications of complex proteins are two obvious drawbacks of these 
bacterial systems. Take the class I hydrophobin HGFI of Grifola frondosa as an example, 
this fungal protein has been successfully expressed in both Escherichia coli (Wang et al. 
2010a) and Pichia pastoris (Wang et al. 2010b) protein expression systems. In E. coli, 
HGFI is acquired as insoluble and miss-folded inclusion bodies, thus succeeding 
solubilization and re-folding operations are needed (Wang et al. 2010a), which are either 
technically difficult to achieve or time-consuming (Marston 1986; Daly and Hearn 2005; 
Tsujikawa et al. 1996). In addition, E. coli produced heterologous proteins usually tend to 
have an extra methionine residue (translation initiator) in their innate N-terminals, which 
may pose a negative effect on protein activity and stability (Chaudhuri et al. 1999). In 
contrast, in P. pastoris, HGFI is obtained in its biologically active form, and, more 
importantly, its innate N-terminal sequence is well retained (Wang et al. 2010b). Other 
fungal hydrophobins, initially produced as non-functional inclusion bodies through 
production in E. coli, but obtained in their active forms when produced in P. pastoris, 
including the class II hydrophobin HFBI of Trichoderma reesei (Nakari-Setälä et al. 1996; 
Niu et al. 2012b) and the class I hydrophobin EAS of Neurospora crassa (Kwan et al. 2006; 
Winefield 2004).  
 
The P. pastoris protein expression system, except for allowing heterologous proteins to be 
produced in their innate active forms, the increased popularity of this system can be 
attributed to several additional factors: (1) the capability of performing eukaryotic 
post-translational modifications, especially for target proteins with multiple disulfide 
bridges or in need of glycosylation (Cereghino and Cregg 2000); (2) the ability of 
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producing heterologous proteins at high levels (Daly and Hearn 2005); (3) the availability 
of systematic genetic manipulation techniques and kits, thus the expression system is easy 
to set up and maintain in most laboratories.   
 
Pichia pastoris host strains 
P. pastoris is facultative methylotrophic yeast, which is capable of utilizing methanol as a 
sole source of carbon and energy. The methanol utilization pathway involves several 
enzymes, and the alcohol oxidase (AOX) is the most important one, catalyzing the 
oxidation of methanol to formaldehyde (HCHO) and hydrogen peroxide (H2O2) in 
peroxisomes. 
 
The P. pastoris alcohol oxidase (AOX) is encoded by either the AOX1 or the AOX2 gene, 
and the majority of AOX activity arises from the AOX1 gene (Tschopp et al. 1987; Cregg 
et al. 1989). A wild type P. pastoris strain (e.g. P. pastoris X-33) generally contains both 
AOX (AOX1 and AOX2) genes and primarily uses the AOX1 gene for its methanol 
metabolism. This phenotype is designated as methanol utilization fast (Mut
+
). Once the 
AOX1 gene is disrupted or deleted on purpose, as a result, P. pastoris cells (e.g. P. pastoris 
KM71) are still capable of utilizing methanol via the transcriptionally weaker AOX2 gene 
at a decreased rate, thus giving rise to the phenotype methanol utilization slow (Mut
s
). In 
addition, a rarely addressed phenotype exists for P. pastoris strains (e.g. P. pastoris MC 
100-3) that have deletions at both AOX genes, which are unable to grow on methanol. This 
phenotype is denominated as methanol utilization minus (Mut
-
) (Macauley-Patrick et al. 
2005).  
 
It is not entirely clear that which phenotype (Mut
+
, Mut
s
 and Mut
-
) is the most suitable one 
for expression of a given protein (Hellwig et al. 2001). However, for extracellular 
production of heterologous proteins, Mut
+
 strains are more often used than Mut
s
 strains, 
due to their higher growth rates and better environmental adaptabilities (Hohenblum et al. 
2004; Slibinskas et al. 2004). This phenotype (Mut
+
) can easily be identified either by 
growing P. pastoris cells on minimal dextrose (MD) and minimal methanol (MM) plates 
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sequentially (Vassileva et al. 2001), or by colony PCR with specific primers 5’ AOX1 and 
3’ AOX1 (Linder et al. 1996).  
 
Protein degradation has long been a problem associated with P. pastoris protein production 
practices, due to the action of endogenous proteases (e.g. vacuole peptidase A). The use of 
protease defect strains (e.g. SMD1168) has proven to reduce protein degradation in many 
heterologous protein production studies with this system (Cereghino and Cregg 2000; 
Macauley-Patrick et al. 2005).  
 
Table 2. Pichia pastoris expression host strains  
Strain  Genotype Phenotype Reference 
X-33 
GS115 
KM71 
SMD1168 
MC 100-3     
wild-type 
his4 
△aox1:: SARG4 his4 arg4 
△pep4::URA3 his4  
△aox1: :SARG4△aox2: :Phis4 
his4 arg4  
Mut
+
, His
+
 
Mut
+
, His
-
 
Mut
s
, His
-
 
Mut
+
, His
+
  
Mut
-
, His
-
 
Li et al. 2001 
Cregg et al. 1985 
Cregg and Madden 1987 
White et al. 1995 
Cregg et al. 1989 
his4: Histidine dehydrogenase defective type. △aox1: Alcohol oxidase I defective type.  
△aox2: Alcohol oxidase II defective type. △pep4: Vacuole peptidase A defective type.  
△arg4: Argininosuccinate lyase defective type.  
 
Pichia pastoris expression vectors  
There is a wide range of commercially available vectors that can be used to express 
heterologous proteins in P. pastoris (Table 3). All P. pastoris expression vectors have been 
designed as an E. coli/P. pastoris shuttle vector. Therefore, an origin of replication for 
vector maintenance and replication in E. coli, AOX1 promoter or alternative promoters, 
one or more restriction sites for insertion of foreign genes, and selection markers functional 
in one or both host organisms are needed (Cereghino and Cregg 2000). 
 
pPIC9 (Figure 12) is a commercially available P. pastoris expression vector that has been 
intensively used for the production of hydrophobins (Niu et al. 2012a; Wang et al. 2010b; 
Niu et al. 2012b) and antimicrobial peptides (Zhang et al. 2005; Zhang et al. 2000). Except 
for the basic features that cited above, this vector contains the functional histidine 
dehydrogenase gene (HIS4), which can be used as a selection marker for the 
transformation of histidine dehydrogenase defective (his4) strains (e.g. GS115, KM71, 
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SMD1168). In addition, to facilitate the extracellular production of heterologous proteins, 
an extracellular secretion signal sequence (usually, alpha-mating factor of Saccharomyces 
cerevisiae) is incorporated upstream of the multiple cloning site (MCS). 
 
 
Figure 12. Vector diagram of pPIC9 (Figure adapted from Pichia expression kit user guide, MAN0000012, 
Lifetechnologies) 
 
Table 3. Commercially available P. pastoris expression vectors 
Name Secretion signal Selection maker Promoter 
pPIC9 
pPIC9K 
pPICZαA 
pGAPZαA 
pHIL-D2 
pHIL-S1 
pP-αSUMOstar 
α-MF 
α-MF 
α-MF 
α-MF 
no 
PHO1 
α-MF 
HIS4, Amp
R 
AmpR, Kan
R
 
Zeo
R
 
Zeo
R
 
HIS4, Amp
R 
HIS4, Amp
R 
Zeo
R
 
AOX1 
AOX1 
AOX1 
GAP 
AOX1 
AOX1 
AOX1 
Secretion signals: α-MF (S. cerevisiae α-mating factor); PHO1 (P. pastoris acid phosphatase). 
Selection markers: Amp
R
 (ampicillin resistance); Kan
R
 (kanamycin resistance); Zeo
R
(zeocin resistance); 
HIS4 (histidine dehydrogenase).  
Promoters: GAP (glyceraldehyde-3-phosphate dehydrogenase); AOX1 (alcohol oxidase 1). 
More information can be found at www.lifetechnologies.com. 
 
To date, a wide range of fungal origin hydrophobins have been successfully expressed in  
P. pastoris, including HFBI (Niu et al. 2012), HFBII (Kottmeier et al. 2011) and Hfb2 
(Lutterschmid et al. 2011) of Trichoderma reesei, FcHyd5p and FcHyd3p of Fusarium 
culmonrum (Lutterschmid et al. 2011; Stübner et al. 2010), HGFI of Grifola frondosa 
(Wang et al. 2010b), RodA and RodB of Aspergillus fumigatusin (Pedersen et al. 2011) and 
EAS of Neurospora crassa (Winefield 2004). 
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EXPERIMENTAL RESEARCH 
3 AIMS OF THE STUDY 
The aim of this study was to explore the feasibility of using recombinant fusion 
hydrophobins to control bacterial growth. The specific aims were: 
1. To construct expression vectors that can thus be used to transform P. pastoris with a 
view to obtain two recombinant fusion hydrophobins, Bac8c-HGFI and 
P11-5-linker-HGFI. 
2. To express these two recombinant fusion hydrophobins in P. pastoris and purify them 
from the culture medium. 
3. To determine the minimum inhibition concentrations (MICs) of these two recombinant 
fusion hydrophobins against bacteria. 
4 MATERIALS AND METHODS 
4.1 Materials 
4.1.1 Bacteria and yeast strains, plasmids, oligonucleotides and primers  
Pichia pastoris GS115 (Genotype: his4; Phenotype: His
-
, Mut
+
) and X-33 (Wild type; 
Phenotype: Mut
+
) strains were kindly provided by Dr. Kristiina Hildén (University of 
Helsinki, Finland). Library Efficiency® DH5α™ Competent Cells (Genotype: F- 
Φ80lacZΔM15 Δ (lacZYA-argF) U169 recA1 endA1 hsdR17 (rK
-
, mK
+
) phoA supE44 λ- 
thi-1 gyrA96 relA1) were purchased from Lifetechnologies (Amsterdam, Netherlands). 
Reference strains Escherichia coli ATCC 8739, Staphylococcus aureus subsp. aureus 
ATCC 12600, Pseudomonas aeruginosa ATCC 10145 and Micrococcus luteus ATCC 4698 
were obtained from HAMBI culture collection center (University of Helsinki, Finland). 
 
Reconstructed P. pastoris expression vectors pPIC9-linker-hgfI preserved in E. coli TG1 
[Genotype: F' (traD36 proAB
+
 lacI
q
 lacZΔM15) supE thi-1 Δ(lac-proAB) 
Δ(mcrB-hsdSM)5, (rK
-
, mK
-
)] and pP-secSUMOpro3-hgfI preserved in E. coli DH5α 
(Genotype: F- Φ80lacZΔM15 Δ (lacZYA-argF) U169 recA1 endA1 hsdR17 (rK
-
, mK
+
) 
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phoA supE44 λ- thi-1 gyrA96 relA1) were kindly provided by Prof. Mingqiang Qiao 
(Nankai University, China). All primers and oligonucleotides (Table 4) were custom 
synthesized by Oligomer Oy (Helsinki, Finland). 
 
Table 4. Overview of primers and oligonucleotides used in this study 
Name Sequence 5’ – 3’ 
5’ AOX 
3’AOX 
α-factor  
p11-5 forward 
p11-5 reverse 
AMP forward 
hgfI reverse 
hgfI
a
 
bac8c
a
 
GACTGGTTCCAATTGACAAGC  
GCAAATGGCATTCTGACATCC  
TACTATTGCCAGCATTGCTGC 
TCGAGAAAAGAGGTAAGTTGTTCAAGAAGATCTTGAAGATCTTGG 
AATTCCAAGATCTTCAAGATCTTCTTGAACAACTTACCTCTTTTC 
CAATCAATGAAACTGACA 
TGGTGGCCGGGTCGTTCG 
CAACAGTGCACCACTGGCCA 
TCTTCTCCAAATAACCCAAATTCTACCTCCCGTCTGCTGCTGGA 
a 5’-phosphorylated  
4.1.2 Antimicrobial peptides, chemical reagents and culture media components 
Antimicrobial peptides Bac8c and P11-5 were custom synthesized by Thermoscientific 
(Germany) using the solid phase method and standard 9-fluorenyl-methoxy-carbonyl 
(FMOC) chemistry. These peptides were purified to > 95% purity using reversed-phase 
high performance liquid chromatography (RP-HPLC). Mass spectrometry was used to 
confirm the peptide identity.  
 
All chemical regents and culture media components were purchased from Sigma-Aldrich 
(Germany), Merck (Germany) or Lab M (Heywood, UK) unless otherwise stated.   
4.2 Methods  
All techniques used for the molecular biology experimental work were based upon these 
standard protocols found in Molecular Cloning: A Laboratory Manual (Green and 
Sambrook, 2012) and Cold Spring Harbor Online Protocols (http://cshprotocols.cshlp.org/) 
unless otherwise stated.   
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4.2.1 Isolation and purification of plasmid DNA from Escherichia coli 
Glycerol stock of E. coli TG1 cells containing the reconstructed P. pastoris expression 
vector pPIC9-linker-hgfI was streaked onto a freshly prepared LB agar plate (1% [w/v] 
trypton, 0.5% [w/v] yeast extract, 1% [w/v] sodium chloride, 1.5% [w/v] agar) containing 
100 μg/ml ampicillin. In the same way, glycerol stock of E. coli DH5α cells containing the 
reconstructed P. pastoris expression vector pP-secSUMOpro3-hgfI was streaked onto a 
freshly prepared low salt LB agar plate (1% [w/v] trypton, 0.5% [w/v] yeast extract, 0.5% 
[w/v] sodium chloride, 1.5% [w/v] agar) containing 50 μg/ml zeocin (Invitrogen, Carlsbad, 
CA, USA). These plates were incubated overnight at 37℃ until single colonies appeared.  
 
A single colony from the LB agar plate was inoculated into 5 ml LB broth (1% [w/v] 
trypton, 0.5% [w/v] yeast extract, 1% [w/v] sodium chloride) containing 100 μg/ml 
ampicillin (for E. coli DH5α, 5 ml low salt LB broth [1% [w/v] trypton, 0.5% [w/v] yeast 
extract, 0.5% [w/v] sodium chloride] containing 50 μg/ml zeocin was used), and incubated 
at 37℃ with shaking at 200 rpm until OD600 reached 0.4 (log-phase growth, approximately 
8 hours). Bacterial cells were collected by centrifugation (Sigma 1-14 Microfuge) for 5 
min at 12000g. Plasmid DNA was extracted from bacterial pellets and purified with 
GeneJET Plasmid Miniprep Kit (Thermoscientific) according to the manufacturer’s 
instructions, and stored in a sterile nuclease-free Eppendorf tube at -20℃ . The 
concentrations of DNA samples were measured by NanoDrop-1000 Spectrophotometer 
(Thermoscientific). 
4.2.2 DNA agarose gel electrophoresis 
Separation and visualization of DNA fragments was performed by agarose gel 
electrophoresis. The percentage (w/v) of agarose (Lonza, Basel, Switzerland) used was 
varied between 1% and 3% depending on the size of the DNA fragments. Gel solutions 
were prepared with 1x TAE buffer (40 mM tris-HCl, 40 mM glacial acetic acid, 1 mM 
EDTA, pH 8.0) and ethidium bromide was added to a final concentration of 0.5μg/ml. 
DNA samples were pre-mixed with 6x DNA Loading Dye (Thermoscientific) prior to gel 
loading. 1 kbp GeneRuler™ DNA Ladder (Thermoscientific) or 100 bp plus GeneRuler™ 
DNA ladder (Thermoscientific) was used as a marker of molecular mass and run parallel to 
  
24 
the DNA samples. Electrophoresis was carried out in 1x TAE buffer at 80 V. Complete gels 
were observed and image captured with Gel Doc XR+ imaging system (Bio-Rad 
Laboratories, Hercules, CA, USA).  
4.2.3 Construction of pP-secSUMOpro3-bac8c-hgfI  
The inverse fusion PCR (IF-PCR) (Figure 13) was conducted with Phusion® Hot Start II 
High-Fidelity DNA polymerase (Thermoscientific) (Table 5). 5’ phosphorylated primers 
(bac8c and hgfI) were designed using a protocol described by Spiliotis (2012). Yield 
optimization was performed with respect to the annealing temperature via gradient PCR in 
Bio-Rad C1000 Thermal Cycler under the following conditions: 98℃ for 1 min, 30 cycles 
of 98℃ for 10 s, (63℃-75℃) for 30 sec, 72℃ for 2 min, and a final extension step at 72℃ 
for 10 min. The PCR products were analyzed on 1% agarose gel. 
 
Table 5. Pipetting instructions for the inverse fusion PCR reaction  
Component Volume (μl) Final concentration 
5X Phusion HF Buffer 
Phusion Hot Start II DNA polymerase (2 U/μl) 
hgfI (10 μM) 
bac8c (10 μM) 
pP-secSUMOpro3-hgfI (template, 1 ng/μl) 
dNTPs (10 mM) 
ddH2O 
10 
0.5 
2.5 
2.5 
1 
1 
32.5  
1x 
0.02 U/μl 
0.5 μM  
0.5 μM  
0.02 ng/μl 
200 μM each 
 
The required DNA band was excised from the agarose gel with x-tracta™ Gel Extractor 
(Promega, Madison, WI, USA) on an UV transilluminator (Bio-Rad Laboratories) and 
subsequently purified with GeneJET Gel Extraction Kit (Thermoscientific) following the 
manufacturer’s instructions. 
 
For self-circularization of blunt-ended PCR products, the reaction mixture was prepared as 
follows: 50 ng blunt-ended linear DNA, 2 μl 10x T4 DNA ligase buffer, 1 μl T4 DNA 
ligase (5 Weiss/μl, Thermoscientific), 2 μl PEG 4000 (50% [w/v]) and ddH2O to a total 
volume of 50 μl. The reaction mixture was incubated at 22℃ for 2 h, and the ligase was 
heat inactivated at 65℃ for 10 min. 
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Figure 13. Outline of inverse fusion PCR (IF-PCR). For IF-PCR, a PCR master mix containing 5’ 
phosphorylated primer bac8c with the insert, circular plasmid template and 5’ phosphorylated primer hgfI 
was prepared. The bac8c primer was annealed with the complementary sequence (black) within the plasmid 
forward strand (2.1 & 2.2), the insert (white) was elongated by overlap extension (2.3), thus generating the 
single-stranded DNA (ssDNA) template with the insert (2.4). The complementary strand of the ssDNA 
template was generated by primer extension of primer hgfI, finalizing the double-stranded DNA (dsDNA) 
template (2.5), which was now exponentially amplified via primers bac8c and hgfI. The linear insert-plasmid 
fusions were self-circularized by T4-ligation (2.6) (Figure adapted from Spiliotis 2012). 
4.2.4 Construction of pPIC9-p11-5-linker-hgfI  
Restriction endonuclease (RE) digestion of pPIC9-linker-hgfI  
The freshly prepared vector pPIC9-linker-hgfI from the plasmid isolation step (section 
4.2.1) was double-restricted with FastDigest®
 
EcoRI and XhoI restriction endonucleases 
(Thermoscientific). The double REs digestion was performed under the optimal reaction 
condition described by the manufacturer.  
 
One step phosphorylation and annealing of oligonucleotides  
As oligonucleotides (p11-5 forward and p11-5 reverse) used in this study are supplied 5’ 
non-phosphorylated. Therefore, to improve the ligation efficiency, T4 polynucleotide 
kinase (T4 PNK, Thermoscientific) was used to phosphorylate oligonucleotides. The 
reaction mix was prepared and the one-step phosphorylation and annealing reaction was 
carried out in Bio-Rad C1000 Thermal Cycler (Table 6). 
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Table 6. Pipetting instructions and thermocycler program for the one-step phosphorylation and annealing 
reaction of oligonucleotides 
Reaction mix composition Thermocycler program 
Component 
10X T4 PNK buffer A 
T4 PNK (10 U/μl) 
p11-5 forward (10 μM) 
p11-5 reverse (10 μM) 
ATP (10 mM) 
ddH2O 
Volume (μl) 
2 
2 
1 
1 
4 
10 
Step 
1 
2 
3 
4 
5 
6 
Temperature (℃) 
37 
95 
95 (-1/cycle) 
74 
74(-1/cycle) 
4 
Time 
30 min 
5 min 
1 min/cycle 
30 min 
1 min/cycle 
∞ 
 
Ligation of DNA fragments  
The 5’ phosphorylated double-stranded oligo (ds oligo) fragment synthesized from the 
previous step was ligated into the prepared pPIC9-linker-hgfI vector. For DNA insert 
ligation into vector DNA, the reaction mixture was prepared as follows: 100 ng linear 
vector DNA, 10: 1 molar ratio of insert DNA over vector, 2 μl 10x T4 DNA ligase buffer, 
0.2 μl T4 DNA ligase (5 Weiss/μl, Thermoscientific), and ddH2O to a total volume of 20 μl. 
The reaction mixture was incubated overnight at room temperature (20℃). 
 
 
Figure 14. Outline of annealed oligo cloning. A short double-stranded oligo (ds oligo) fragment was 
synthesized by annealing oligonucleotides p11-5 forward and p11-5 reverse, with sticky ends specific to XhoI 
and EcoRI restriction endonucleases in 5’- and 3’-terminus, respectively. The double-stranded oligo fragment 
was ligated into the prepared pPIC9-linker-hgfI vector by T4-ligation.   
4.2.5 Transformation of electrocompetent Escherichia coli DH5α cells 
Electrocompetent E. coli DH5α cells from -80℃ storage were thawed on ice. 1 μl ligation 
mix (from section 4.2.3 or section 4.2.4) was added to 50μl cells, gently mixed and 
transferred to a pre-chilled 2 cm disposable electroporation cuvette (VWR International, 
Germany). Electroporation was conducted with a Gene Pulser™ apparatus (Bio-Rad 
Laboratories) set at 2.5 kV, 200 Ω and 25 μF. Immediately after the electroporation, 950 μl 
SOC broth (Lifetechnologies) was added to the cuvette and a total volume of 1 ml bacterial 
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suspension was transferred to a sterile Eppendorf tube and placed on a shaking incubator at 
37℃ for 1 hour. The bacterial cells were then plated out on selection agar plates with the 
corresponding antibiotics and incubated overnight at 37℃ until single colonies appeared.  
4.2.6 Colony PCR  
Colony PCR was used as a rapid method to screen ligation reactions for positive clones. 
Visible bacterial colonies were picked from selection agar plates with pipette tips, 
suspended in 10 μl nuclease-free ddH2O and thoroughly mixed by vortex. 1 μl bacterial 
liquid was directly added to the PCR master mix as the DNA template (Table 7).  
 
The colony PCR was conducted with vector specific primers in Bio-Rad C1000 Thermal 
Cycler under the following conditions: 94℃ for 5 min, 30 cycles of 94℃ for 1 min, 53℃ 
for 1 min, 72℃ for 8 sec, and a final extension step at 72℃ for 10 min. The PCR 
products were analyzed on 3% agarose gel. Two colony PCR verified positive 
transformants were sent for sequencing (Institute of Biotechnology, University of Helsinki, 
Finland).  
 
Table 7. Pipetting instructions for E. coli colony PCR 
Component  Volume (μl) Final concentration  
10X optimized DyNAzyme buffer 
10 mM dNTPs 
α-factor/AMP forward (10 μM)a 
hgfI reverse (10 μM) 
Bacterial liquid (DNA template) 
DyNAzyme II polymerase (2 U/μl) 
H2O 
2 
0.4 
1 
1 
1  
0.2  
14.4 
1x 
200 μM each 
0.5 μM 
0.5 μM 
 
0.02 U/μl 
a 
primers AMP forward and hgfI reverse were used for E. coli transformants that transformed with the 
pP-secSUMOpro3-bac8c-hgfI ligation mix, and primers α-factor and hgfI were used for E. coli transformants 
that transformed with the pPIC9-p11-5-linker-hgfI ligation mix.  
4.2.7 Transformation of electrocompetent Pichia pastoris cells
 
The sequencing-confirmed P. pastoris expression vector pPIC9-p11-5-linker-hgfI was 
linearized with StuI (Thermoscientific) (for pP-secSUMOpro3-bac8c-hgfI, PmeI was used). 
The linearized vector DNA was concentrated by isopropanol precipitation, suspended in a 
small amount of nuclease-free Milli-Q water and subsequently used to transform 
electrocompetent P. pastoris GS115 cells (for pP-secSUMOpro3-bac8c-hgfI, 
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electrocompetent P. pastoris X-33 cells were used). Electroporation was conducted with a 
Gene Pulser™ apparatus set at 2.0 kV, 200 Ω and 25 μF. Immediately after the 
electroporation, 1 ml 1M ice cold sterile sorbitol was added to the cuvette and the cell 
suspension was transferred to a 15 ml Falcon™ tube and left to incubate for 2 hours at 28℃ 
without shaking. Electrocompetent P. pastoris GS115 and X-33 cells were prepared using a 
protocol described by Cereghino et al. (2005).  
 
For P. pastoris GS115 transformants, cells were initially plated on MD (minimal dextrose) 
agar plates (1.34% [w/v] YNB, 4 × 10
-5
 % [w/v] biotin, 2% [w/v] dextrose, 1.5% [w/v] 
agar) and incubated at 30℃ for 3-4 days until single colonies appeared. Subsequently, 
thirty colonies (His
+
) were picked from MD agar plates and pasted on MM (minimal 
methanol) agar plates (1.34% [w/v] YNB, 4 × 10
-5
 % [w/v] biotin, 0.5% [v/v] methanol, 
1.5% [w/v] agar) to identify the methanol utilization type. For P. pastoris X-33 
transformants, cells were initially plated on YPDS agar plates (1% [w/v] yeast extract, 2% 
[w/v] peptone, 2% [w/v] dextrose, 1 M sorbitol, 2% [w/v] agar) containing 100 μg/ml 
zeocin and incubated at 30℃ for 3-4 days until single colonies appeared. Subsequently, 
twenty zeocin-resistant colonies were picked from YPDS agar plates and further polished 
on YPD agar plates (1% [w/v] yeast extract, 2% [w/v] peptone, 2% [w/v] dextrose, 2% 
[w/v] agar) containing 100 μg/ml zeocin. 
 
Table 8. Pipetting instructions and thermocycler program for P. pastoris colony PCR 
PCR master mix composition Thermocycler program 
Component 
10X standard Taq buffer 
10 mM dNTPs 
5’ AOX1 (10 μM) 
3’ AOX1 (10 μM) 
Hot start Taq DNA polymerase
a
  
Template DNA 
ddH2O 
Volume (μl)  
2 
0.4 
1 
1 
0.2  
1  
to 20 
Step 
1 
2 
3 
4 
5 
6 
7 
Temperature (℃) 
95 
95 
54 
68 
go back to 2 
68 
4 
Time 
3 min 
30 s 
30 s 
2.2 min 
35 cycles 
5 min 
∞ 
a 
New England Biolabs(NEB) 
 
The fast-growing/zeocin-resistant transformants were further analyzed by colony PCR with 
primers 5’ AOX and 3’ AOX (Table 8). To obtain the genomic DNA template for PCR, 
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single colonies were picked and lysed with 0.2% hot SDS treatment (microwave oven set 
at full power) for 2 min. Cell debris was then pelleted by a pulse spin in a bench top 
centrifuge and the supernatant was directly used for PCR analysis. 
4.2.8 Inducible expression of recombinant fusion hydrophobins   
The colony PCR-validated P. pastoris transformants together with the corresponding 
control strains (P. pastoris GS115 transformed with pPIC9, P. pastoris X-33 transformed 
with pP-secSUMOpro3) were used for a small-scale trial expression of recombinant fusion 
proteins.  
 
For optimal expression, P. pastoris transformants and control strains were initially 
inoculated into 25 mL buffered minimal glycerol (BMG) broth (100 mM potassium 
phosphate, 1.34% [w/v] yeast nitrogen base, 4 x 10
-5
% [w/v] biotin, 1% [v/v] glycerol, pH 
6.0) and grown at 30℃ with shaking at 280 rpm until OD600 reached 2-6 (log-phase 
growth, approximately 16-18 hours). These cultures were centrifuged for 5 min at 3000g 
and pelleted cells were suspended in 50 mL buffered minimal methanol (BMM) broth (100 
mM potassium phosphate, 1.34% [w/v] yeast nitrogen base, 4 x 10
-5
% [w/v] biotin, 0.5% 
[v/v] methanol, pH 6.0). Cultures were grown for 96/120 h at 30℃ with shaking at 280 
rpm, filter-sterilized methanol was added to a final concentration of 0.5% (v/v) every 24 h. 
Meanwhile, 1 ml culture samples were taken at 24 h intervals for protein expression 
analysis. After 96 h/120 h of cultivation, culture supernatants were collected by 
centrifugation (8000g, 10 min, JA-14, Beckman Avanti™ J-251) and stored in sterile 
SCHOTT® glass bottles (Duran, Germany) at -80℃.  
4.2.9 Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) of 
proteins 
Tricine-SDS-PAGE with the discontinuous pH system described by Schägger (2006) was 
used to separate and visualize small proteins/peptides. Culture supernatant samples from 
the previous step were concentrated by trichloroacetic acid (TCA) precipitation, mixed 
with Tricine Sample Buffer (Bio-Rad) containing 125 mM dithiothreitol (DTT) and heated 
immediately for 10 minutes at 95℃. Spectra Multicolor Low Range Protein Ladder 
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(Thermoscientific) was loaded as a marker of size. Gels were run at 30 V through the 
stacking gel and 200 V through the separating gel. When the electrophoresis had finished, 
gels were stained with Silver Stain Plus Kit (Bio-Rad). 
 
Glycine-SDS-PAGE with the discontinuous pH system originally described by Laemmli 
(1970) was used to separate and visualize proteins. Culture supernatant samples were 
concentrated by acetone precipitation, mixed with 2x Laemmli Sample Buffer (Bio-Rad) 
containing 355 mM 2-mercaptoethanol and heated immediately for 10 minutes at 95℃. 
Spectra Multicolor Low Range Protein Ladder (Thermoscientifc) was loaded as a marker 
of size (for Western blot analysis, 7-175 kDa prestained protein marker [New England 
Biolabs] was used). Gels were run at 100 V through the stacking gel and 200 V through the 
separating gel. When the electrophoresis had finished, complete gels were stained for three 
hours and de-stained, using laboratory stocks of filtered Coomassie staining solution (0.04% 
[w/v] Coomassie Brilliant Blue R-250, 40% [v/v] methanol, 10% [v/v] glacial acetic acid) 
and de-staining solution (10% [v/v] glacial acetic acid), respectively. 
4.2.10 Western blot analysis of the recombinant fusion hydrophobin 
SUMO3-Bac8c-HGFI  
Western blot originally reported by Towbin et al. (1979) was used as a more sensitive and 
specific approach for visualizing proteins. Culture supernatant samples were initially 
separated with Glycine-SDS-PAGE as described in section 4.2.9. Instead of staining, 
proteins on SDS-PAGE gel were electro-blotted to a polyvinylidene fluoride (PVDF) 
membrane (Pall, Port Washington, NY, USA) with a wet-transfer apparatus (Bio-Rad) set 
at 30 V for 2 h. After transfer, the PVDF membrane was blocked in the blocking solution 
(WesternBreeze®, Invitrogen) at room temperature for 30 minutes.  
 
Transferred proteins were probed with the primary antibody anti-Penta·His IgG1 (Mouse, 
1:1000 dilution) (Qiagen, Netherlands) for 1 h at room temperature. After rinsed three 
times with the antibody wash solution (WesternBreeze®, Invitrogen), alkaline phosphatase 
(AP) conjugated Goat anti-Mouse IgG (H+L) secondary antibody (1:5000 dilution) (Pierce, 
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Rockford, IL, USA) was added and left to bind for 1 h and visualized with BCIP/NBT 
Color Development Substrate (Promega). 
4.2.11 Purification of the recombinant fusion hydrophobin SUMO3-Bac8c-HGFI  
The recombinant fusion hydrophobin SUMO3 [6x His-tag]-Bac8c-HGFI was purified with 
Ni-NTA slurry (Invitrogen) following the manufacturer’s instructions. The purified protein 
solution was transferred into an Amicon Ultra-15 ultrafiltration unit (Millipore) and buffer 
exchanged against phosphate buffered saline (PBS) solution (137 mM NaCl, 2.7 mM KCl, 
10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4) to remove imidazole and chemical impurities.  
 
SUMO protease 2 (Lifesensors, Malvern, PA, USA) was added to the substrate (1 unit 
enzyme to 10-100 μg target fusion protein) to remove the SUMO3 fusion tag. The reaction 
was performed overnight at 4℃. In the same way, the SUMO3 fusion tag and SUMO 
protease 2 in the digestion mixture was removed with Ni-NTA slurry and buffer exchanged 
against ultrapure Milli-Q water. The purified protein solution was then lyophilized and 
stored at -80℃.   
4.2.12 Purification of the recombinant fusion hydrophobin P11-5-linker-HGFI  
Culture supernatant samples were separated with 16% Tricine-SDS-PAGE as described in 
section 4.2.9, instead, gel was stained with Coomassie staining solution (10% acetic acid, 
40% methanol and 0.1% Coomassie Brilliant Blue-R250). The required protein band was 
excised from the gel and eluted with Model 422 Electro-Eluter apparatus (Bio-Rad) 
following the manufacturer’s instructions. In short, the excised protein gel slice was placed 
into an Electro-Eluter capsule and the electroelution was performed at 50 V for 12 h at 4℃ 
in Tris-glycine buffer (25 mM Tris-HCl, 250 mM glycine, 0.1% [v/w] SDS). Eluent in the 
membrane cap was collected and transferred into an Amicon Ultra-4 ultrafiltration unit 
(Millipore) and buffer exchanged against ultrapure Milli-Q water to remove chemical 
impurities. The protein solution was then lyophilized and stored at -80℃. 
 
 
  
32 
4.2.13 Dot blot analysis of the recombinant fusion hydrophobin P11-5-linker-HGFI   
The purified recombinant fusion hydrophobin P11-5-linker-HGFI was analyzed by dot blot, 
2 μl protein solution was directly applied to a PVDF membrane (Pall) via a micropipette 
and air-dried at room temperature for at least 30 min. The PVDF membrane was then 
blocked in the blocking solution (WesternBreeze®, Invitrogen) at room temperature for 30 
minutes.  
 
Proteins on the PVDF membrane were probed with the primary antibody anti-rHGFI 
(1:1000 dilution) (from a male New Zealand white rabbit, Nankai University, China) for 1 
h. After rinsed three times with the antibody wash solution (WesternBreeze®, Invitrogen), 
alkaline phosphatase (AP) conjugated secondary antibody anti-Rabbit IgG (Fc) (1:3000 
dilution) (Promega) was left to bind for 1 h and visualized with BCIP/NBT Color 
Development Substrate (Promega). 
4.2.14 Protein quantification  
Protein quantification was performed with Modified Lowry Protein Assay Kit (Pierce, 
Waltham, MA, USA) following the manufacturer’s instructions. 
4.2.15 Minimum inhibitory concentration test  
Minimum inhibitory concentrations (MICs) were determined using a modified microplate 
dilution method described by Wiegand et al. (2008). Reference bacteria were grown to a 
mid-log phase (OD600 ≈ 0.4) in Mueller-Hinton broth (BD Difco™) and diluted to 2-7 x 
10
5 
CFU/ml inoculum sizes.  
 
Antimicrobial peptides and purified fusion proteins were serial diluted to obtain final 
concentrations of 200, 100, 50, 25, 12.5, 6.25 and 3.1 μg/ml, respectively (Qi et al. 2010; 
Hilpert et al. 2005). Meanwhile, bacterial growth control with no test peptides/proteins and 
environmental sterility control with no bacterial cells were prepared. Plates were incubated 
at 37℃ for  24 h and bacterial growth was determined with Infinite 200 microplate 
reader (Tecan, Switzerland) set at 600 nm. The experiment was independently repeated two 
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times. MIC was defined as the lowest concentration that needed to reduce bacterial growth 
by more than 50% after 24 hours (Wiegand et al. 2008). 
4.2.16 Tools for data analyses  
1. Thermoscientific Tm calculator was used to predict the annealing temperature for PCR 
or sequencing. 
2. NEBcutter V2.0 was used to determine the potential endonuclease cleavage sites of 
vectors. 
3. NCBI Nucleotide BLAST was used to generate sequence alignments for DNA 
sequence comparison. 
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5 RESULTS 
5.1 Construction of pP-secSUMOpro3-bac8c-hgfI  
Yield optimization of inverse fusion PCR (IF-PCR) was performed with respect to the 
annealing temperature via gradient PCR. In lanes 1-5, a band was apparent above 4 kbp. 
The no-template control in lane C did not display any bands (Figure 15). 
 
 
Figure 15. 1% agarose gel displaying inverse fusion PCR products. Lane L: Generuler™ 1 kbp DNA ladder. 
Lanes 1-5: gradient PCR products (from left to right, 65℃, 67℃, 69℃, 71℃, 73℃). Lane C: No-template 
control. 
 
The >4 kbp DNA fragment was purified from the agarose gel, self-circularized and 
transformed into E. coli DH5α cells. Eight zeocin-resistant transformants growing on 
selection plates were picked and analyzed by colony PCR with vector specific primers. In 
lanes 5, 6 and 9, a band was apparent below 200 bp. In lanes 2-4, 7 and 8, three bands were 
apparent below 1000 bp, between 1000 bp and 1200 bp, and above 1200 bp, respectively. 
The positive control (E. coli DH5α transformed with pP-secSUMOpro3-hgfI) in lane 1 
displayed a band around 150 bp. The negative control (E. coli DH5α cells) in lane C did 
not show any bands (Figure 16C).  
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Figure 16. (A) Schematic representation of the reconstructed P. pastoris expression vector 
pP-secSUMOpro3-bac8c-hgfI. (B) The amino sequence of the recombinant fusion hydrophobin Bac8c-HGFI. 
(C) 3% high-resolution agarose gel (Sigma-Aldrich, Germany) displaying E. coli colony PCR products. Lane 
L: Generuler™ 100 bp Plus DNA ladder. Lane 1: positive control (E. coli DH5α transformed with 
pP-secSUMOpro3-hgfI). Lane C: negative control (E. coli DH5α cells). Lanes 2-9: eight zeocin-resistant E. 
coli transformants.  
5.2 Expression of the recombinant fusion hydrophobin SUMO3-Bac8c-HGFI 
The sequencing-confirmed expression vector pP-secSUMOpro3-bac8c-hgfI was linearized 
with PmeI and subsequently transformed into P. pastoris X-33 cells. Six zeocin-resistant  
P. pastoris transformants growing on selection plates were picked and analyzed by colony 
PCR with primers 5’AOX1 and 3’AOX1. In lanes 1-6, two clear bands were apparent 
above 2 kbp and above 1 kbp, respectively (Figure 17). 
 
 
Figure 17. 1% agarose gel displaying P. pastoris colony PCR products. Lane L: Generuler™ 1 kb DNA 
ladder. Lanes 1-6: six zeocin-resistant P. pastoris X-33 transformants. 
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Six P. pastoris X-33 clones identified as positive transformants by colony PCR together 
with the control strain (P. pastoris X-33 transformed with pP-secSUMOpro3) were 
subjected to a small-scale trial expression. After the expression was induced with 0.5% 
methanol for 96 h, supernatant samples from each induced culture were collected, 
concentrated and analyzed by SDS-PAGE. Two protein bands with apparent molecular 
weights of 40 kDa and > 40 kDa were observed in all six P. pastoris X-33 transformants 
(lanes 1-6, Figure 18A), but not in the control strain at the corresponding positions (lane C, 
Figure 18A). Western blot showed a protein with apparent molecular weight of 80 kDa 
could react positively (purple band) with the protein specific primary antibody, which was 
observed in all six P. pastoris X-33 transformants (lanes 1-6, Figure 18B), but not in the 
control strain at the corresponding position (lane C, Figure 18B).  
 
 
Figure 18. (A) Coomassie stained 12% SDS-PAGE analysis of the recombinant fusion hydrophobin 
SUMO3-Bac8c-HGFI expressed in P. pastoris X-33. Lane L: Spectra™ multicolor low range protein ladder. 
Lanes 1-6: six P. pastoris X-33 transformants. Line C: control strain (P. pastoris X-33 transformed with 
pP-secSUMOpro3). (B) Western blot analysis of the recombinant fusion hydrophobin SUMO3-Bac8c-HGFI 
expressed in P. pastoris. Lane L: Prestained protein marker (7-175 kDa, NEB). Lane C: control strain (P. 
pastoris X-33 transformed with pP-secSUMOpro3). Lanes 1-6: six P. pastoris X-33 transformants. Primary 
antibody: 1:1000 anti-Penta·His IgG1 (Mouse). Secondary antibody: 1:3000 Goat anti-Mouse IgG (H+L), AP 
conjugate. Color development substrate: NBT/BCIP.  
5.3 Minimum inhibitory concentrations of the recombinant fusion hydrophobin 
Bac8c-HGFI  
The SUMO3 fusion tag was removed from the fusion protein SUMO3-Bac8c-HGFI by 
protease digestion followed by an affinity chromatography cleaning step. Minimum 
inhibitory concentrations (MICs) of the antimicrobial peptide Bac8c and the recombinant 
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fusion hydrophobin Bac8c-HGFI against E. coli, S. aureus, P. aeruginosa and M. luteus 
were measured. A summary of results can be found in Table 9. The MIC of Bac8c was 3.1 
μg/ml against E. coli, S. aureus and M. luteus, respectively, and 12.5 μg/ml against P. 
aeruginosa. There was no detectable growth inhibition effect of the recombinant fusion 
hydrophobin Bac8c-HGFI in all tested bacteria strains.   
 
Table 9. Minimum inhibitory concentrations (μg/ml) of the recombinant fusion hydrophobin Bac8c-HGFI 
and the antimicrobial peptide Bac8c  
 Minimum inhibitory concentration (MIC), μg/ml 
Name E. coli P. aeruginosa S. aureus  M. luteus 
Bac8c 
Bac8c
a
 
Bac8c-HGFI 
3.1 
2 
N.D 
12.5 
8 
N.D. 
3.1 
2 
N.D. 
3.1. 
N.A. 
N.D. 
a 
Values were obtained from Hilpert et al. 2005. 
N.A.: not available. N.D.: not detectable. 
5.4 Construction of pPIC9-p11-5-linker-hgfI  
The double-stranded oligo (ds oligo) fragment containing the encoding sequence of the 
antimicrobial peptide P11-5 was ligated into the expression vector pPIC9-linker-hgfI and 
transformed into E. coli DH5α cells. Seven ampicillin-resistant colonies growing on 
selection plates were picked and analyzed by colony PCR with vector specific primers. In 
lanes 2-8, a band was apparent below 200 bp. The positive control (E. coli DH5α 
transformed with pPIC9-linker-hgfI) in lane 1 displayed a band around 150 bp. The 
negative control (E. coli DH5α cells) in lane C did not show any bands (Figure 19C). 
 
 
Figure 19. (A) Schematic diagram of the reconstructed P. pastoris expression vector pPIC9-p11-5-linker-hgfI. 
(B) The amino acid sequence of the recombinant fusion hydrophobin P11-5-linker-HGFI. (C) 3% 
high-resolution agarose gel displaying the colony PCR products. Lane L: Generuler™ 100 bp Plus DNA 
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ladder. Lane 1: positive control (E. coli DH5α transformed with pPIC9-linker-hgfI). Lanes 2-8: seven 
ampicillin-resistant E. coli transformants. Lane C: Negative control (E. coli DH5α cells).  
5.5 Expression of the recombinant fusion hydrophobin P11-5-linker-HGFI  
The sequencing-confirmed expression vector pPIC-p11-5-linker-hgfI was linearized with 
StuI and transformed into P. pastoris GS115 cells. Six fast-growing P. pastoris GS115 
transformants on MM agar plates were picked and analyzed by colony PCR with primers 
5’AOX1 and 3’AOX1. In lanes 1-6, two clear bands were apparent above 2 kbp and above 
750 bp, respectively (Figure 20). 
 
 
Figure 20. 1% agarose gel displaying the colony PCR amplification products. Lane L: Generuler™ 1kb DNA 
ladder. Lanes 1-6: Six P. pastoris GS115 transformants. 
 
Six P. pastoris GS115 clones identified as positive transformants by colony PCR together 
with the control strain (P. pastoris GS115 transformed with pPIC9) were subjected to a 
small-scale trial expression. After the expression was induced with 0.5% methanol for 96 h, 
supernatant samples from each induced culture were collected, concentrated and analyzed 
by Tricine-SDS-PAGE. A band with apparent molecular weight of <15 kDa was observed 
in all six P. pastoris GS115 transformants (lanes 1-6, Figure 21A), but not in the control 
strain at the corresponding position (lane C, Figure 21A). Dot blot analysis showed that the 
eluent from the <15 kDa protein band could react positively (purple) with the protein 
specific antibody (Figure 22).  
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Figure 21. (A) Silver-stained 16% Tricine-SDS-PAGE analysis of the recombinant fusion hydrophobin 
P11-5-linker-HGFI expressed in P. pastoris GS115. Lane L: Spectra™ multicolor low range protein ladder. 
Lanes 1-6: six P. pastoris GS115 transformants. Line C: control strain (P. pastoris GS115 transformed with 
pPIC9). (B) Silver-stained 4-15% SDS-PAGE (Mini-PROTEAN® TGX™ Precast Protein Gel, Bio-Rad) 
analysis of the recombinant fusion hydrophobin P11-5-linker-HGFI expressed in P. pastoris GS115 
transformant one. Lane L: Spectra™ multicolor low range protein ladder. Lanes 1-5: culture supernatant 
samples collected after 24, 48, 72, 96, 120 hours of induction, respectively. Lane C: control strain (P. pastoris 
GS115 transformed with pPIC9). 
 
 
Figure 22. Dot blot analysis of the eluent from the <15 kDa band. 1: P. pastoris GS115 transformant one. 
Dot 2: P. pastoris transformant two. Dot C: control strain (P. pastoris GS115 transformed with pPIC9). 
Primary antibody: anti-rHGFI antibody (rabbit source). Secondary antibody: Anti-Rabbit IgG (Fc), AP 
conjugate. Color development substrate: NBT/BCIP. 
 
Meanwhile, time course analysis to determine the optimal induction time for the 
production of P11-5-linker-HGFI was performed, daily supernatant samples of 
transformant one were collected and analyzed by SDS-PAGE. A protein band with 
apparent molecular weight of <15 kDa was observable after 24 h, increasing in intensity up 
to 96 h or 120h (Figure 21B). 
5.6 Minimum inhibitory concentration of the recombinant fusion hydrophobin 
P11-5-linker-HGFI  
Minimum inhibitory concentration (MICs) of the antimicrobial peptide P11-5 and the 
recombinant fusion hydrophobin P11-5-linker-HGFI against E. coli were measured. A 
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summary of results can be found in Table 10. The MIC of P11-5 was 3.1 μg/ml against   
E. coli. The MIC of the fusion protein P11-5-linker-HGFI was 100 μg/ml against E. coli.  
 
Table 10. Minimum inhibitory concentrations (μg/ml) of the recombinant fusion hydrophobin 
P11-5-linker-HGFI and the antimicrobial peptide P11-5  
Minimum inhibitory concentration (MIC, μg/ml) 
Name E. coli 
P11-5 
P11-5
a
 
P11-5-linker-HGFI 
3.1 (3.1μM) 
3.1 
100 (9.1μM) 
a
 Value was obtained from Qi et al., 2010. N.D.: no detectable. 
 
As shown in Figure 23, abnormal cell clumps were observed, when E. coli cells were 
treated with the fusion protein P11-5-linker-HGFI at concentrations (25 and 50 μg/ml) 
below the MIC (100 μg/ml). The treated E. coli culture had a cloudy and yellowish 
appearance. 
 
 
Figure 23. Light microscopic images of E. coli ATCC 9027 untreated, and treated with 50 μg/ml and 25 
μg/ml purified recombinant fusion hydrophobin P11-5-linker-HGFI for 24 h. Macroscopic appearances of  
E. coli culture untreated and treated with 50 μg/ml purified recombinant fusion hydrophobin 
P11-5-linker-HGFI for 24 h. 
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6 DISCUSSION  
6.1 Molecular cloning, expression and characterization of the recombinant fusion 
hydrophobin Bac8c-HGFI  
In this study, Pichia pastoris X-33 strain was used to express the recombinant fusion 
hydrophobin Bac8c-HGFI, as it secretes extremely low levels of endogenous proteins, 
which in turn could facilitate purification of the expressed fusion protein from the culture 
medium (Cereghino and Cregg 2000). More importantly, being a fungus, P. pastoris shares 
the similar post-translation modification (PTM) strategies and extended glycosylation 
modes of hydrophobins as Grifola frondosa (Wang et al. 2010b), and thus may ensure that 
the hydrophobin HGFI domain of the fusion protein Bac8c-HGFI could be processed to its 
optimally active form (Niu et al. 2012a; Huang et al. 2013).  
 
Heterologous expression of antimicrobial peptides is facing two challenges. Firstly, the 
peptide’s antimicrobial nature makes it potentially lethal to the expression host (Parachin et 
al. 2012; Li 2009). Secondly, the peptide’s linear structure and high base amino acid 
content makes it highly vulnerable to proteolytic degradation in all steps of the expression 
(Raimondo et al. 2005). Thus, in order to achieve successful heterologous expression, the 
antimicrobial peptide is usually fused to a chaperone protein to mask its cytotoxicity 
against the host cells (Lee et al. 2000; Parachin et al. 2012). To date, many fusion 
chaperone proteins have been used successfully to express a wide range of 
host-unfavorable antimicrobial peptides, including thioredoxin (Xie et al. 2013), small 
ubiquitin-like modifiers (SUMO) (Li et al. 2013; Wang et al. 2014) and 
phosphoribosyltransferase (PurF) (Lee et al. 2000). Following this approach, the 
reconstructed P. pastoris expression vector pP-secSUMOpro3-hgfI that carries the human 
SUMO3 gene and the hgfI gene isolated from Grifola frondosa (GenBank Accession 
NO.EF486307) was used to achieve secretory expression of the recombinant fusion 
hydrophobin Bac8c-HGFI in P. pastoris.     
 
Inverse fusion PCR cloning (IFPC) is a seamless in-frame cloning strategy, requires simple 
starting materials, one step routine PCR, and generally results in the insertion of the 
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foreign gene into a wide range of plasmids with high success rates (Spiliotis 2012). To 
perform a successful IFPC, high-fidelity DNA polymerases (with proofreading activity) 
that generate blunt-ended PCR products should be used, since blunt ends are mandatory for 
the final self-circularization step (Garrity and Wold 1992; Spiliotis 2012). In this study, the 
encoding sequence of the antimicrobial peptide Bac8c (bac8c) was successfully cloned 
into the vector (pP-secSUMOpro3-hgfI) backbone by IFPC, which was confirmed by 
colony PCR as the corresponding band (174 bp fragment) was observed by gel 
electrophoresis (lanes 5, 6 and 9, Figure 16C) and sequencing. Although the primer pair 
(hgfI and bac8c) used in this study was calculated (Tm Calculator, Thermoscientific) to 
have an average annealing temperature of 72℃, PCR with either lower or higher annealing 
temperatures did also provide very good amplification performances (Figure 15), 
demonstrating that IFPC could be successfully carried out even under some non-ideal 
conditions.  
 
On the other hand, two drawbacks of IFPC emerged in this study: (1) non-specific PCR 
amplification products formed (data not shown) probably due to primer mismatching 
(Arnheim and Erlich 2000; Spiliotis 2012). This problem was successfully solved with a 
hot start PCR protocol to allow for more specific primer binding during the annealing step 
(Zhang and Gurr 2000); (2) high background of false positive clones (5/8, lanes 2-4 and 
7-8, Figure 16C), which was likely due to poly-circularization of the blunt-ended PCR 
products.   
 
To perform a reliable colony PCR screening of P. pastoris positive transformants, the 
proposed protocols usually involve a lyticase pretreatment followed by extraction and 
purification of genomic DNA template for PCR analysis (Linder et al. 1996; Lin et al. 
2012). However, in practice, preparation of genomic DNA template is either tedious or 
time-consuming (Haaning et al. 1997). Instead of this, I developed a hot SDS method for 
rapid preparation of crude genomic DNA template for PCR analysis (section 4.2.7). This 
method was reliably used in the whole study (Figure 17 and 20). The colony PCR results 
confirmed the integration of pP-secSUMO3pro-bac8c-hgfI into all six P. pastoris X-33 
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transformants tested (1093 bp fragment, Figure 17). Meanwhile, all six transformants were 
also confirmed with the phenotype Mut
+
 (2.2 kbp fragment, Figure 17). 
 
Dimerization and tetramerization of hydrophobins in an SDS-PAGE gel due to the 
self-assembly of hydrophobins into stable polymers in aqueous solutions (de Vries et al. 
1993) was reported in many studies with hydrophobins (Hakanpää et al. 2006; Kisko et al. 
2008; Wang et al. 2004; Szilvay et al. 2007). In the expression study, two unique proteins 
with apparent molecular masses of 40 kDa and >40 kDa were identified in all P. pastoris 
X-33 transformants (Figure 18A). These two values were inconsistent with the theoretical 
value (21 kDa) of the fusion protein SUMO3-Bac8c-HGFI, which would probably be a 
dimer (40 kDa ≈ 2 x 21 kDa) and a tetramer of the fusion protein SUMO3-Bac8c-HGFI. 
The >40 kDa protein could react positively with the fusion protein specific primary 
antibody (Figure 18B). These results indicate that the fusion protein SUMO3-Bac8c-HGFI 
was expressed and secreted into the culture medium, but subsequently self-assembled into 
polymers. 
  
Protease cleavage of the SUMO3 fusion tag followed by an affinity chromatography 
cleaning step was not successful as expected, only 1.04 mg fusion protein Bac8c-HGFI 
was recovered from 100 mL culture broth (data not shown), probably because the 
purification protocol (more details can be seen in the Ni-NTA purification system user 
manual [25-0496], Invitrogen) that I used has not been optimized for hydrophobins yet. In 
the following minimum inhibitory concentration test, the results showed that the highly 
active antimicrobial peptide Bac8c became inactivated when it was fused with the 
hydrophobin HGFI (Table 9). Similarly, in an earlier study, Rieder et al. (2014) found that 
a highly active antimicrobial peptide became inactivated when it was fused with the class I 
hydrophobin DewA of Aspergillus nidulans. To the best of my knowledge, steric hindrance 
between the adjacent domains (Bac8c and HGFI) might have been responsible for this 
inactivation (Linder et al. 2002; Iwanaga et al. 2011). 
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6.2 Molecular cloning, expression and characterization of the recombinant fusion 
hydrophobin P11-5-linker-HGFI  
Flexible polypeptide linkers, generally composed of small, non-polar amino acids (e.g. 
glycine, serine and threonine) are often used in fusion protein studies when the adjacent 
domains require a certain degree of spacing to reduce unfavorable inter-domain 
interferences (Chen et al. 2013b). Following this approach, a 10-mer flexible polypeptide 
linker (NH2-GGGGSGGGGS), which has been used successfully in an earlier fusion 
hydrophobin study (Niu et al. 2012a) was employed to construct the recombinant fusion 
hydrophobin P11-5-linker-HGFI. 
 
The double-stranded oligo (ds oligo) fragment (p11-5) encoding the antimicrobial peptide 
P11-5 was successfully subcloned into the expression vector pPIC9-linker-hgfI, which was 
confirmed by colony PCR as the corresponding band (188 bp fragment) was observed by 
gel electrophoresis (lanes 2-9, Figure 19C) and sequencing. When the p11-5 fragment and 
the hgfI gene were fused, the linker sequence was laid between them, in order to reduce the 
steric hindrance between the adjacent peptide (P11-5) and protein (HGFI), when the fused 
gene (p11-5-linker-hgfI) was translated into protein (Figure 19B). In addition, the innate 
nucleotide sequence encoding the STE13 protease cleavage site (Glu-Ala-Glu-Ala) was 
deleted when the p11-5 fragment was inserted into the XhoI site of pPIC9-linker-hgfI. 
Although Glu-Ala repeats has been recommended in many studies, in order to ensure that 
the protein secretory signal (in this study, α-MF of saccharomyces cerevisiae) could be 
processed correctly in the endoplasmic reticulum of P. pastoris (Sreekrishna and Kropp 
1996). However, there are numerous cases where STE13 cleavage of Glu-Ala repeats is not 
sufficient enough as expected, and thus Glu-Ala repeats are left on the N-terminus of the 
expressed protein (Kim et al. 1997; Emberson et al. 2005), which in turn may pose a 
negative effect on the activity and stability of the expressed protein (Wu and Hancock 
1999). For example, Cabral et al. (2013) found that the P. pastoris produced Pisum sativum 
defensin 1 (Psd1), which contained Glu-Ala repeats on its innate N-terminal region 
presented at least 10-fold decrease in antifungal activity, as compared with the native 
counterpart. In this study, the KEX2 protease cleavage site (Lys-Arg) was designed to be 
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located after the XhoI site, in order to ensure that the fusion protein P11-5-linker-HGFI 
could be secreted into the culture medium with an intact N-terminus. 
  
The colony PCR results confirmed the integration of pPIC9-p11-5-linker-hgfI into all six  
P. pastoris GS115 transformants tested (784 bp fragment, Figure 20). All tested 
transformants were also confirmed with the phenotype Mut
+
 (2.2 kbp fragment, Figure 20). 
In the expression study, all six P. pastoris GS115 transformants could produce a unique 
protein with apparent molecular mass of <15 kDa (Figure 21A). This value was 
inconsistent with the theoretical value (10.3 kD) of the fusion protein P11-5-linker-HGFI. 
This phenomenon was similar with those found in earlier studies (Tagu et al. 2001; Wang 
et al. 2010a). For example, Wang et al. (2010a) found that the apparent molecular weight 
(14 kDa) of the recombinant hydrophobin HGFI was slightly higher than its theoretical 
size (10.9 kDa). This change in gel mobility is proposed to be due to an insufficient 
reduction of the intramolecular disulfide bonds within hydrophobins during the sample 
pretreatment step, thus resulting in a retarded gel mobility (Cumming et al. 2004; Tagu et 
al. 2001). The eluent from the <15 kDa protein band could react positively with the 
primary antibody raised against the hydrophobin HGFI (Figure 22), which indicates that 
the fusion protein P11-5-linker-HGFI was successfully expressed and secreted into the 
culture medium.  
 
The antibacterial activity of the antimicrobial peptide P11-5 against E. coli as determined 
in this study was well conformed to the literature value (Table 10). In contrast, the peptide 
represented 3-time reduced antibacterial activity when it was fused with the hydrophobin 
HGFI, in terms of the molecular concentration (Table 10). It is well acknowledged that the 
length of polypeptide linker may affect the cytoplasmic membrane penetration efficiency 
of tethered antimicrobial peptides (Qi et al. 2011). Many of the existing studies have 
demonstrated that a tethered antimicrobial peptide would exhibit better activities, if a long 
and flexible polypeptide linker is used (Bagheri et al. 2009). More specifically, Robinson et 
al. (1998) concluded that polypeptide linkers of more than 10-mer in length are excellent 
candidates for fusion proteins. In this fusion protein construct, a relatively short 
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polypeptide linker (10-mer) was used, which may still not sufficient long enough to 
prevent the reciprocal interference between the adjacent domains.  
 
There is currently no clear explanation for this abnormal aggregation behavior of E. coli 
cells, when they were treated with the fusion protein P11-5-linker-HGFI at concentrations 
that below the MIC (Figure 23). It is well known that the cell-wall-associated 
hydrophobins play an important role in facilitating the aggregation of filamentous hyphal 
cells into large clumps (Talbot 1997). Based on this fact, Nakari-Setälä et al. (2002) 
engineered the cell wall of Saccharomyces cerevisiae with the class II hydrophobin HFBI 
of Trichoderma reesei, increased cell-cell adhesion (clumping) ability was observed among 
these hydrophobin-modified yeast cells, as compared with the unmodified counterpart. The 
proposed cell-killing mechanism of the antimicrobial peptide P11-5 is the ‘carpet-like’ 
mode of action. Therefore, if the concentration of peptides is not sufficient enough to 
disintegrate the bacterial cytoplasmic membrane, they are bound parallel onto the bacterial 
cytoplasmic membrane (Brogden 2005), thus leading to the immobilization of the attached 
hydrophobins on the bacterial surface. In the aqueous environment, these bacterial surface 
immobilized hydrophobins would self-assembly into polymers, and thereby resulting in the 
aggregation of bacterial cells.  
6.3 Future work: specific-protease-enhanced antibacterial fusion hydrophobins 
Many pathogenic microorganisms possess unique proteases to invade host organisms 
(Aoki and Ueda 2013). For example, Listeria monocytogenes, the bacterium that causes the 
invasive infection listeriosis, secretes a stress-induced serine protease that plays a crucial 
role in intracellular survival of this pathogen (Gaillot et al. 2000). On the basis of this, 
designing fusion antimicrobial peptides that can be activated by species-specific proteases 
may provide high selectivity toward each target pathogenic microorganism. Following this 
postulation, Aoki et al. (2012) designed a fungicidal fusion protein (Figure 24) that could 
be exclusively activated by a unique aspartic protease of Candida albicans. This peptide 
showed a highly selective in vitro activity against C. albicans, but not against other tested 
microorganisms, which do not possess the corresponding aspartic protease. 
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Figure 24. Schematic diagram of the aspartic protease-activated fungicidal fusion protein. This peptide is 
composed of three functional domains: an antimicrobial peptide, a protective peptide and a 
protease-cleavable linker. Generally, the fungicidal activity of the tethered antimicrobial peptide is inhibited 
by the protective peptide. Species-specific protease cleaves the linker and subsequently releases the 
antimicrobial peptide, causing its activation (Figure adapted from Aoki and Ueda, 2013).       
 
The potential cleavage site analysis of the fusion protein P11-5-linker-HGFI demonstrated 
that this protein contains an endoprotease AspN cleavage site, which is located in the 
C-terminal region of the antimicrobial peptide. Therefore, upon the enzymatic digestion 
with AspN, the antimicrobial peptide P11-5 could be neatly released from the fusion 
protein. In the future work, once we confirmed that the enzymatic digestion could improve 
the antibacterial activity of the fusion protein. By using the design approach described by 
Aoki et al. (2012), a series of specific-protease-enhanced antimicrobial hydrophobins could 
thus be designed. 
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7 CONCLUSIONS 
In summary, two recombinant fusion hydrophobins, Bac8c-HGFI and P11-5-linker-HGFI 
were successfully expressed and secreted into the culture medium. Similar to hydrophobins, 
the fusion protein Bac8c-HGFI could form stable polymers in the aqueous environment. 
The highly active antimicrobial peptide Bac8c became inactivated when it was fused with 
the hydrophobin HGFI. Interestingly, the hydrophobin HGFI gained an acquired 
antibacterial nature when it was fused with the antimicrobial peptide P11-5 through a 
10-mer flexible polypeptide linker, with the minimum inhibitory concentration of 100 
μg/ml against Escherichia coli. However, there is currently no clear explanation for the 
abnormal aggregation behavior of E. coli cells in this study. Further experiments are 
needed to clarify this issue. 
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